NPR News: Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment

Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.

Đọc thêm tại NPR
at August 8, 2019 at 04:00PM
Health & Science